Biocept Bets on Oncology Testing

09/12/2018 5:00 am EST


Michael Murphy

Former Editor, New World Investor

Michael Murphy is a long-standing expert on leading edge technologies; one section in his New World Investor newsletter features a portfolio of high risk, high return biotech stocks. Here, he looks at Biocept (BIOC), a developer of a blood tests that may help in the treatment of cancer patients.

Biocept has said that Highmark Health is testing its "liquid biopsy" platform designed to help oncologists improve the diagnosis and treatment of patients with non-small cell lung cancer.

The goals are to improve health outcomes by using liquid biopsy to more rapidly assess a patient’s molecular status and select an appropriate therapy, while also reducing the overall cost of care.

Highmark Health is the second-largest US integrated delivery and financing system. Their VITAL Innovation Program focuses on real-world testing of early-stage health innovations, producing evidence related to patient experience, and care and cost outcomes.

The evidence can accelerate an innovation’s insurance coverage and utilization by health plans and care delivery systems, fast-tracking the solution to patients and supporting swifter marketplace adoption.

More than 100 patients of Highmark Health-affiliated Allegheny Health Network Cancer Institute in Pittsburgh will participate. I expect a very good outcome compared to tissue biopsy, as we have seen many times already.

This could jump-start Biocept’s revenue growth. BIOC is a Hold in our portfolio for a $30 target in a potential acquisition. Meanwhile, the primary risk for this company is that they run out of money.

Subscribe to New World Investor here…

Related Articles on HEALTHCARE